Drugs / Bromopride
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02604576 | Jan 2017 → Mar 2018 | dyspepsia | EMS | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bromopride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02604576 ↗ |
| Known as | Bromoprida | ChEMBL registry synonym — accepted as the source's own label CHEMBL399510 ↗ |
| Known as | Movipride | ChEMBL registry synonym — accepted as the source's own label CHEMBL399510 ↗ |
| Known as | NSC-758391 | ChEMBL registry synonym — accepted as the source's own label CHEMBL399510 ↗ |
| Action | Inhibit | “Dopamine D2 receptor antagonist” CHEMBL399510 ↗ |
| Modality | Small molecule | — CHEMBL399510 ↗ |
| Target | DRD2 | “Dopamine D2 receptor antagonist” CHEMBL399510 ↗ |